National mass drug administration costs for lymphatic filariasis elimination

PLoS Neglected Tropical Diseases

Volumn 1, Issue 1, 2007, Pages

  Goldman, Ann S ^a   Guisinger, Victoria H ^b   Aikins, Moses ^c   Amarillo, Maria Lourdes E ^d   Belizario, Vicente Y ^d   Garshong, Bertha ^c   Gyapong, John ^c   Kabali, Conrad ^e   Kamal, Hussein A ^f   Kanjilal, Sanjat ^b   Kyelem, Dominique ^g   Lizardo, Jefrey ^h   Malecela, Mwele ^e   Mubyazi, Godfrey ^e   Nitlèma, P Abdoulaye ^g   Ramzy, Reda M R ⁱ   Streit, Thomas G ^j   Wallace, Aaron ^b   Brady, Molly A ^b   Rheingans, Richard ^b   Ottesen, Eric A ^b   Haddix, Anne C ^b   more..

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c Health Research Unit Ghana Health Service   (Ghana)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^f MINISTRY OF HEALTH   (Egypt)

^g MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^h INTEC University   (Dominican Republic)

ⁱ AIN SHAMS UNIVERSITY   (Egypt)

^j UNIVERSITY OF NOTRE DAME   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN; ANTHELMINTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; DRUG COST; ENDEMIC DISEASE; FILARIASIS; FINANCIAL MANAGEMENT; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION RISK; INTERNATIONAL COOPERATION; LYMPHATIC SYSTEM DISEASE; POPULATION SIZE; PUBLIC HEALTH; RESOURCE ALLOCATION; RISK ASSESSMENT; BURKINA FASO; CLINICAL TRIAL; COST; DOMINICAN REPUBLIC; DRUG THERAPY; ECONOMICS; EGYPT; ELEPHANTIASIS; GHANA; HAITI; LYMPHATIC FILARIASIS; METHODOLOGY; MULTICENTER STUDY; PATIENT CARE; PHILIPPINES; TANZANIA;

ALBENDAZOLE; ANTHELMINTICS; BURKINA FASO; COSTS AND COST ANALYSIS; DIETHYLCARBAMAZINE; DOMINICAN REPUBLIC; DRUG THERAPY; EGYPT; ELEPHANTIASIS; ELEPHANTIASIS, FILARIAL; GHANA; HAITI; HUMANS; PATIENT CARE TEAM; PHILIPPINES; TANZANIA;

EID: 43349095895     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000067     Document Type: Article

References (25)

1. World Health Organization (2006) Global Programme to Eliminate Lymphatic Filariasis. WER 81(22): 221-232.
2. Ramaiah K, Das P, Michael E, Guyatt H (2000) The economic burden of lymphatic filariasis in India. Parasitology Today 16(6): 251-253.
3. Gyapong J, Gyapong M, Evans D, Aikins M, Adjei S (1996) The economic burden of lymphatic filariasis in northern Ghana. Annals of Tropical Medicine & Parasitology 90(1): 39-48.
4. UN Office of the High Representative for the Least Developed Countries. List of Least Developed Countries. Available at: http://www.un.org/ special-rep/ohrlls/ldc/list.htm. Accessed November 15, 2005.
5. Galvez Tan J (2003) The elimination of lymphatic filariasis: A strategy for poverty alleviation and sustainable development - Perspectives from the Philippines. Filaria J 2(12).
6. Durrheim D, Wynd S, Liese B, Gyapong J (2004) Editorial: Lymphatic filariasis endemicity an indicator of poverty? Tropical Medicine & International Health 9(8): 843-845.
7. CDC (1993) Recommendations of the International Task Force for Disease Eradication. Morbidity & Mortality Weekly Report.Recommendations & Reports 42(RR-16): 1-38.
8. Ismail M, Jayakody R, Weil GJ, Nirmalan N, Jayasinghe K, Abeyewickrema W, et al. (1998) Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine & Hygiene 92(1): 94-97.
9. Ottesen E (2000) The global programme to eliminate lymphatic filariasis. Tropical Medicine & International Health 5(9): 591-594.
10. Ramaiah K, Guyatt H, Ramu K, Vanamail P, Pani S, Das P (1999) Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Tropical Medicine & International Health 4(1): 19-25.
11. Krishnamoorthy K, Rajendran R, Sunish I, Reuben R (2002) Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis. Annals of Tropical Medicine & Parasitology 96(Suppl 2): S77-90.
12. de Rochars M, Kanjilal S, Direny A, Radday J, Lafontant J, Mathieu E, et al. (2005) The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. American Journal of Tropical Medicine & Hygiene 73(5): 888-894.
13. Laxminarayan R, Mills AJ, Breman J, Measham A, Alleyne G, Claeson M, et al. (2006) Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 367(9517): 1193-1208.
14. World Bank Group. World Development Indicators Database. Available at: http://www.worldbank.org/data/countrydata/countrydata.html. Accessed November 15, 2004.
15. United Nations Development Programme (2004) Human Development Reports. Accessed November 15, 2004.
16. Ramzy R, Goldman A, Kamal H (2005) Defining the cost of the Egyptian lymphatic filariasis eliminination program. Filaria J 4.
17. Haddix A, Teutsch SM, Corso PS (2003) Prevention Effectiveness: A guide to decision analysis and economic evaluation. Second ed. New York: Oxford University Press.
18. McFarland D, Menzies N, Njoumemi Z, Onwujekwe O (August 2005) Study of cost per treatment with ivermectin using the CDTI strategy. African Programme for Onchocerciasis Control (APOC).
19. Onwujekwe O, Chima R, Shu E, Okonkwo P (2002) Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy 62(1): 31-51.
20. World Health Organization (2005) Deworming for health and development: Report of the third annual meeting of the Partners for Parasite Control. WHO/CDS/CPE/PVC/2005.14. Geneva: WHO.
21. Kumaresan J, Mecaskey J (2003) The global elimination of blinding trachoma: progress and promise. American Journal of Tropical Medicine & Hygiene 69(5 Suppl): 24-28.
22. Fenwick A, Molyneux D, Nantulya V (2005) Achieving the Millennium Development Goals.see commentcomment. Lancet 365(9464): 1029-1030.
23. Brady M, Hooper P, Ottesen E (2006) Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol 22(7): 285-291.
24. World Health Organization (2005) World Malaria Report. Geneva: WHO.
25. World Health Organization (2004) Progress Report on the Global Plan to Stop Tuberculosis. Geneva: WHO.